FYI ...

800,000

Estimated number of Americans living with a history of melanoma

Source: Skin Cancer Foundation

Connect to Us

Digital Edition

FDA OKs ipilimumab for melanoma

Washington — The Food and Drug Administration (FDA) has approved Bristol-Myers Squibb's Yervoy (ipilimumab) for treatment of metastatic melanoma. Read full article.

Zostavax earns expanded approval

Washington — The Food and Drug Administration (FDA) has approved the use of Zostavax (Merck), a live attenuated Varicella zoster virus vaccine, for the prevention of shingles in people ages 50 to 59 years old. The drug previously was approved for use in people ages 60 and older. Read full article.

Oral cancer drug in phase 2 trials

Zurich — Roche officials say phase 2 trials of vismodegib, the company's experimental oral skin cancer drug, suggest that the treatment has the ability to shrink advanced basal cell carcinoma tumors in some patients, Dow Jones Newswires reports. Read full article.

Protein may help harness tumors

London — New research suggests that a protein associated with wound healing could prove helpful in preventing the spread of tumors or fibrosis, Medical News Today reports. Read full article.

Vitamin D deficit, Parkinson's linked

Atlanta — Patients with recent-onset Parkinson's disease (PD) tend to have a high prevalence of insufficient vitamin D levels, but — contrary to expectation — concentrations of the vitamin do not appear to decline as the disease progresses, Medical News Today reports. Read full article.

Arthritis drug slows tumor growth

Boston — A drug commonly used to treat rheumatoid arthritis also appears capable of inhibiting the growth of malignant melanoma, ScienceDaily.com reports.
Read full article.

Career Opportunities

Louisiana State University Health Science	Siong Chuan Lee MD Inc
David A High MD	Dartmouth-Hitchcock Medical Center
Greenville Hospital System

Contact Us

Contact a Dermatology Times editor Click Here
Contact a Dermatology Times sales representative Click Here
Learn about direct mail, reprints and classifieds in Dermatology Times Click Here

You are subscribed to %%list.name%% as %%emailaddr%%. Click here to unsubscribe or edit your member profile.

To ensure delivery to your inbox, please add us to your address book. If you need help doing this, Click here.

Advanstar Communications provides certain customer contact data (such as customers' names, addresses, phone numbers and e-mail addresses) to third parties who wish to promote relevant products, services and other opportunities which may be of interest to you. If you do not want Advanstar Communications to make your contact information available to third parties for marketing purposes, simply call (toll free) 866-529-2922 at any time, or
fax us at 218-740-6417. Outside the U.S., please phone 218-740-6395. Contact us by mail at Advanstar Communications Inc., 131 West First St., Duluth, MN 55802-2065, USA.